Organizations Filed Purposes:
THE MISSION OF DNDI NORTH AMERICA IS TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GLOBAL OBJECTIVES, IN PARTICULAR TO STRENGHTEN AND EXPAND DNDI'S SCIENTIFIC, POLICY ADVOCACY, FUNDRAISING, AND COMMUNICATIONS EFFORTS IN NORTH AMERICA BY (A) PROVIDING FOCUSED SUPPORT FOR SPECIFIC R&D PROJECTS AND BUSINESS/PARTNER DEVELOPMENT ACTIVITIES IN NORTH AMERICA;(B) ACHIEVING CONCRETE POLICY CHANGES IN NORTH AMERICA TO CREATE A MORE FAVORABLE ENVIRONMENT FOR NEEDS-DRIVEN R&D FOR NEGLECTED DISEASES;(C) MOBILIZING PUBLIC AND PRIVATE FUNDS IN NORTH AMERICA TO SUPPORT DNDI'S MISSION;(D) INCREASING DNDI'S PROFILE AND VISIBILITY IN NORTH AMERICA, THEREBY DRAWING GREATER PUBLIC ATTENTION TO THE NEED FOR NEGLECTED DISEASE R&D.
THE DRUGS FOR NEGLECTED DISEASES INITIATIVE (DNDI), NORTH AMERICA SUPPORTS DNDI'S GLOBAL VISION AND MISSION TO DEVELOP NEW DRUGS, OR NEW FORMULATIONS OF EXISTING DRUGS FOR PATIENTS SUFFERING FROM THE MOST NEGLECTED DISEASES. ACTING IN THE PUBLIC INTEREST, DNDI BRIDGES EXISTING R&D GAPS IN ESSENTIAL DRUGS FOR THESE DISEASES BY INITIATING AND COORDINATING DRUG R&D PROJECTS IN COLLABORATION WITH THE INTERNATIONAL RESEARCH COMMUNITY, THE PUBLIC SECTOR, THE PHARMACEUTICAL INDUSTRY, AND OTHER PARTNERS.
GRANTS TO RESEARCH AND DEVELOPMENT FOR NEGLECTED DISEASES: DNDI NORTH AMERICA RAISES FUNDS TO SUPPORT DNDI'S RESEARCH AND DEVELOPMENT (R&D) ACTIVITIES IN ORDER TO CONTRIBUTE TO THE ACHIEVEMENT OF DNDI'S GOAL OF DELIVERING 16-18 NEW TREATMENTS FOR NEGLECTED PATIENTS BY 2023 AND ESTABLISHING A ROBUST PIPELINE OF NEW POTENTIAL DRUG CANDIDATES. DNDI NOW HAS OVER 30 PROJECTS IN ITS PIPELINE, INCLUDING 13 POTENTIAL NEW CHEMICAL ENTITIES(NCES), AND HAS DELIVERED SEVEN TREATMENTS THAT ARE ALREADY IN THE HANDS OF MILLIONS OF PATIENTS.
RAISING PUBLIC AWARENESS AND ADVOCATING FOR NEGLECTED DISEASE R&D:AS PART OF ITS MISSION, DNDI ADVOCATES FOR ENHANCED POLITICAL LEADERSHIP, INCREASED RESOURCES, AND AN ENABLING POLICY ENVIRONMENT TO STIMULATE R&D FOR NEGLECTED DISEASES. DNDI NORTH AMERICA ACTIVELY ADVOCATES FOR SOUND POLICIES, PARTICULARLY IN THE UNITED STATES, THAT WILL ENABLE GREATER NEEDS-DRIVEN R&D, INCLUDING APPROPRIATE INCENTIVES AND FINANCING MECHANISMS, INNOVATIVE REGULATORY PATHWAYS THAT EXPEDITE ACCESS, AND OPEN INNOVATION APPROACHES TO INTELLECTUAL PROPERTY MANAGEMENT THAT ENSURE THE WIDEST POSSIBLE SHARING OF RESEARCH KNOWLEDGE AND DATA.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Jennifer Katz | DIR EXTERNAL AFFAIRS, GARD | 40 | $178,675 |
| Rachel Cohen | EXECUTIVE DIRECTOR | 40 | $169,812 |
| Ilan Moss | COMMUNICATIONS MANAGER | 40 | $114,388 |
| Brett Engelkemier | TREASURER | 2 | $0 |
| John Lawrence | BOARD MEMBER | 2 | $0 |
| Meena Ahamed | BOARD MEMBER | 2 | $0 |
| Bernard Pecoul | BOARD MEMBER | 2 | $0 |
| Shing Chang | SECRETARY | 2 | $0 |
| Darin Portnoy | CHAIR OF THE BOARD | 3 | $0 |
| Bennett Shapiro | BOARD MEMBER | 2 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202041689349301234_public.xml